SOAP Note: 63-Year-Old Female with Atrial Fibrillation on ECG

SUBJECTIVE

Document the patient's symptoms systematically: palpitations, dyspnea, chest pain, presyncope, exertional intolerance, fatigue, or whether she is entirely asymptomatic (10–40% of AF patients have no symptoms). 1
Clarify the onset and duration: Is this the first detected episode, or has she had prior episodes? If duration is >48 hours or unknown, this directly impacts cardioversion and anticoagulation timing. 22
Screen for precipitating factors: recent alcohol binge, hyperthyroidism, acute illness, pulmonary embolism, myocardial infarction, pericarditis, myocarditis, hypertensive crisis, obstructive sleep apnea. 23
Medication history: Is she on any rate-control drugs (beta-blockers, calcium-channel blockers, digoxin) or anticoagulation already? 3
Past medical history relevant to stroke risk: congestive heart failure, hypertension, diabetes, prior stroke/TIA, vascular disease, age ≥75 years (she is 63, so 0 points for age in CHA₂DS₂-VASc). 22

OBJECTIVE

Vital Signs

Heart rate, blood pressure, respiratory rate, oxygen saturation, temperature. Specifically note if systolic BP <90 mmHg, altered mental status, acute pulmonary edema, ongoing chest pain, or cardiogenic shock—any of these mandate immediate synchronized electrical cardioversion (≥200 J biphasic) without waiting for anticoagulation. 23

Physical Examination

Cardiovascular: Irregularly irregular pulse, absence of a waves in jugular venous pulsation, variable S1 intensity, signs of heart failure (elevated JVP, S3 gallop, pulmonary crackles, peripheral edema). 3
Pulmonary: Assess for pulmonary edema or underlying lung disease (COPD/asthma contraindicate beta-blockers). 23
Neurologic: Focal deficits suggesting prior stroke or TIA. 2

Electrocardiogram (ECG)

Confirm AF: Irregularly irregular rhythm, absence of discrete P waves, fibrillatory waves (f waves) at variable rates. 23
Assess ventricular rate: Rapid (>100 bpm), controlled (60–100 bpm), or slow (<60 bpm). 3
Evaluate for pre-excitation (delta waves): If Wolff-Parkinson-White syndrome is present, all AV-nodal blockers (beta-blockers, calcium-channel blockers, digoxin, adenosine, amiodarone) are absolutely contraindicated because they can precipitate ventricular fibrillation. 23
Measure QRS duration and QTc: Baseline for antiarrhythmic drug monitoring. 23

Laboratory Tests

Thyroid-stimulating hormone (TSH), free T4: Rule out hyperthyroidism. 23
Complete blood count: Assess for anemia (increases bleeding risk on anticoagulation). 2
Comprehensive metabolic panel: Electrolytes (hypokalemia/hypomagnesemia can precipitate arrhythmias), renal function (guides DOAC dosing), hepatic function. 23
Troponin: If chest pain or concern for acute coronary syndrome. 3
Brain natriuretic peptide (BNP) or N-terminal pro-BNP: If heart failure suspected. 3

Imaging

Transthoracic echocardiogram (TTE): Mandatory to assess left atrial size, left ventricular ejection fraction (LVEF), valvular disease (especially mitral stenosis or mechanical valves, which require warfarin over DOACs), and structural abnormalities. 223
Chest X-ray: Evaluate for pulmonary edema, cardiomegaly, underlying lung disease. 3

ASSESSMENT

1. Atrial Fibrillation – Newly Detected or Recurrent

Classify by duration and pattern: First detected, paroxysmal (≤7 days), persistent (>7 days), or permanent. 1
Hemodynamic stability: Stable vs. unstable (see Objective). 23

2. Stroke Risk Stratification (CHA₂DS₂-VASc Score)

Calculate immediately: Congestive heart failure (1), Hypertension (1), Age ≥75 years (2), Diabetes (1), Prior stroke/TIA/thromboembolism (2), Vascular disease (1), Age 65–74 years (1), Female sex (1). 223
For a 63-year-old female with no other risk factors: Score = 1 (female sex only). Consider anticoagulation after individualized bleeding-risk assessment; if any additional risk factor is present (e.g., hypertension, diabetes), score ≥2 → oral anticoagulation is mandatory (Class I). 22

3. Bleeding Risk Assessment

Do not use bleeding-risk scores to withhold anticoagulation; they guide monitoring intensity and modifiable-risk-factor management. 2
Modifiable factors: Uncontrolled hypertension (target <140/90 mmHg), concomitant antiplatelet agents or NSAIDs (minimize duration), alcohol excess, anemia. 2

4. Left Ventricular Function (from TTE)

Preserved LVEF (>40%): Beta-blockers or non-dihydropyridine calcium-channel blockers (diltiazem, verapamil) are first-line for rate control. 23
Reduced LVEF (≤40%) or heart failure: Beta-blockers (bisoprolol, carvedilol, long-acting metoprolol) and/or digoxin only; avoid diltiazem and verapamil (Class III Harm) due to negative inotropic effects. 234

5. Precipitating Factors

Reversible causes identified? Treat underlying condition (e.g., thyrotoxicosis, acute alcohol intoxication, pulmonary embolism). 23

PLAN

A. Immediate Management (Hemodynamic Stability)

If Hemodynamically UNSTABLE (systolic BP <90 mmHg, altered mental status, acute pulmonary edema, ongoing chest pain, cardiogenic shock):

Perform immediate synchronized electrical cardioversion (≥200 J biphasic) without awaiting anticoagulation. Administer concurrent IV heparin bolus if feasible. 23

If Hemodynamically STABLE:

Proceed to rate control and anticoagulation strategy below. 23

B. Anticoagulation for Stroke Prevention

1. Calculate CHA₂DS₂-VASc Score

Score ≥2 (men) or ≥3 (women): Initiate oral anticoagulation immediately (Class I, Level A). 22
Score =1 (men) or =2 (women): Consider anticoagulation after individualized bleeding-risk assessment. 22

2. Choice of Anticoagulant

Direct oral anticoagulants (DOACs) are preferred over warfarin (Class I, Level A) except in patients with mechanical heart valves or moderate-to-severe mitral stenosis. 223
- Apixaban: 5 mg PO BID (or 2.5 mg BID if ≥2 of: age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL). 23
- Rivaroxaban: 20 mg PO daily with evening meal (15 mg daily if CrCl 15–50 mL/min). 2
- Edoxaban: 60 mg PO daily (30 mg daily if CrCl 15–50 mL/min, weight ≤60 kg, or concomitant P-glycoprotein inhibitor). 2
- Dabigatran: 150 mg PO BID (75 mg BID if CrCl 15–30 mL/min or age ≥80 years with high bleeding risk). 2
Warfarin (if DOAC contraindicated): Target INR 2.0–3.0; check INR weekly during initiation, then monthly once stable. 23

3. Peri-Cardioversion Anticoagulation (if cardioversion planned)

AF duration >48 hours or unknown: Provide therapeutic anticoagulation for ≥3 weeks before elective cardioversion and continue for ≥4 weeks afterward. 223
Alternative: Perform transesophageal echocardiography (TEE) to exclude left atrial thrombus; if negative, proceed with cardioversion after initiating heparin, then continue anticoagulation for ≥4 weeks. 23
AF duration <48 hours: May proceed with cardioversion after initiating anticoagulation, but continue for ≥4 weeks post-procedure. 3

4. Long-Term Anticoagulation

Continue anticoagulation indefinitely based on CHA₂DS₂-VASc score, regardless of whether sinus rhythm is restored. In the AFFIRM trial, 72% of strokes occurred in patients who discontinued anticoagulation or had subtherapeutic INR. 3

C. Rate Control Strategy

1. Heart-Rate Targets

Lenient target (initial): Resting heart rate <110 bpm (Class I, Level A). 223
Strict target (if symptoms persist): Resting heart rate <80 bpm, with 90–115 bpm during moderate exertion. 34
Assess rate both at rest and during exertion; resting control does not guarantee adequate control during activity. 34

2. First-Line Agents (Based on LVEF from TTE)

If LVEF >40% (Preserved Systolic Function):

Beta-blockers (preferred):
- Metoprolol tartrate: 25–50 mg PO BID initially, titrate to 100–200 mg daily. 34
- Metoprolol succinate (extended-release): 50–100 mg PO daily, titrate to 200–400 mg daily. 34
- Atenolol: 25–100 mg PO daily. 3
- Bisoprolol: 2.5–10 mg PO daily. 34
- Carvedilol: 3.125–50 mg PO BID. 3
Non-dihydropyridine calcium-channel blockers (alternative if beta-blockers contraindicated):
- Diltiazem: 60–120 mg PO TID or 120–360 mg extended-release daily. 3
- Verapamil: 40–120 mg PO TID or 120–480 mg extended-release daily. 3

If LVEF ≤40% (Reduced Systolic Function or Heart Failure):

Beta-blockers (bisoprolol, carvedilol, long-acting metoprolol) and/or digoxin only. 234
Digoxin: 0.0625–0.25 mg PO daily (no loading dose for outpatient initiation). 34
Avoid diltiazem and verapamil (Class III Harm) due to negative inotropic effects. 234

3. Escalation to Combination Therapy

If monotherapy fails to achieve target heart rate within 4–7 days, add digoxin to the beta-blocker or calcium-channel blocker. Combination therapy provides superior control at rest and during exercise. 34
Monitor closely for bradycardia when combining AV-nodal blockers. 3
Do not combine beta-blocker with calcium-channel blocker except under specialist supervision due to risk of severe bradycardia and heart block. 3

4. Special Populations

Chronic obstructive pulmonary disease (COPD) or active bronchospasm: Prefer non-dihydropyridine calcium-channel blockers (diltiazem or verapamil); avoid beta-blockers. 23
Wolff-Parkinson-White syndrome with pre-excited AF: Avoid all AV-nodal blockers (beta-blockers, calcium-channel blockers, digoxin, adenosine, amiodarone). If unstable, perform immediate DC cardioversion; if stable, use IV procainamide or ibutilide. 23

D. Rhythm Control Considerations

Indications for Rhythm Control:

Consider rhythm control for patients who remain symptomatic despite adequate rate control, younger patients (<65 years) with new-onset AF, those with rate-related cardiomyopathy, or hemodynamically unstable patients. 231
Early rhythm control with antiarrhythmic drugs or catheter ablation is recommended for symptomatic paroxysmal AF or heart failure with reduced ejection fraction (HFrEF) to improve quality of life, left ventricular function, and cardiovascular outcomes. 1

Antiarrhythmic Drug Selection (Based on Cardiac Structure & LVEF):

No structural heart disease (normal LVEF, no coronary artery disease, no LV hypertrophy): Flecainide, propafenone, or sotalol are first-line. 23
Coronary artery disease with LVEF >35%: Sotalol is preferred (requires ≥3 days inpatient ECG monitoring and renal dose adjustment). 3
Heart failure or LVEF ≤40%: Amiodarone or dofetilide are the only safe options; other antiarrhythmics carry high pro-arrhythmic risk. 23

Catheter Ablation:

First-line therapy for symptomatic paroxysmal AF to improve symptoms and slow progression to persistent AF. 1
Recommended for AF patients with HFrEF to improve quality of life, left ventricular systolic function, and reduce mortality and heart failure hospitalization. 1

E. Lifestyle and Risk-Factor Modification

Weight loss (if BMI >25 kg/m²): Achieve ≥10% body-weight loss to reduce AF burden. 2
Blood pressure control: Target <140/90 mmHg (stricter if tolerated). 2
Diabetes management: Optimize glycemic control; consider metformin or SGLT2 inhibitors (may lower AF incidence). 2
Obstructive sleep apnea: Prescribe continuous positive airway pressure (CPAP) therapy. 2
Alcohol reduction: Advise avoidance of binge drinking and alcohol excess. 2
Physical activity: Encourage 150–300 min/week of moderate-intensity or 75–150 min/week of vigorous-intensity aerobic exercise. 2

F. Monitoring and Follow-Up

Renal function: Assess at least annually when using DOACs, more frequently if clinically indicated. 3
INR monitoring (if on warfarin): Weekly during initiation, monthly once stable. 23
Reassess CHA₂DS₂-VASc score: At 6 months after initial presentation and at least annually thereafter. 3
12-lead ECG at follow-up visits: Document rhythm and rate; evaluate for pro-arrhythmic markers (PR, QRS, QT prolongation) if on antiarrhythmic drugs. 3
Repeat TTE: If heart failure develops or if considering rhythm-control interventions. 3

G. Common Pitfalls to Avoid

Do not discontinue anticoagulation solely because sinus rhythm has been restored; stroke risk is determined by CHA₂DS₂-VASc score, not rhythm status. 23
Do not use digoxin as monotherapy for paroxysmal AF or in physically active patients; it fails to control exercise-induced tachycardia. 34
Do not use aspirin alone for stroke prevention; oral anticoagulants are superior. 3
Do not give IV calcium-channel blockers to patients with decompensated heart failure (Class III Harm). 234
Do not assess heart rate solely at rest; always evaluate during exertion. 34

This SOAP note provides a comprehensive, guideline-directed approach to managing a 63-year-old female with newly detected atrial fibrillation, prioritizing stroke prevention, rate control, and individualized rhythm-control strategies based on the most recent ACC/AHA/ESC guidelines.

Please create a SOAP note for a 63-year-old female with atrial fibrillation on electrocardiogram.

Help us tailor your experience